Navigation Links
DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma
Date:3/31/2008

itrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi- synthetic taxane that is in the same drug class as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: http://www.genta.com.

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward- looking statements include, without limitation, statements about:

-- the Company's ability to obtain necessary regulatory approval for

Genasense(R) from the U.S. Food and Drug Administration ("FDA") or

European Medicines Agency ("EMEA");

-- the safety and efficacy of the Company's products or product

candidates;

-- the Company's assessment of its clinical trials;

-- the commencement and completion of clinical trials;

-- the Company's ability to develop, manufacture, license and sell its

products or product candidates;

-- the Company's ability to enter into and successfully execute license

and collaborative agreements, if any;

-- the adequacy of the Company's capital resources and cash flow

projections, and the Company's ability to obtain sufficient financin
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. DSMB Again Supports Continuation of the Phase III Clinical Trial of Medidur(TM) FA for the Treatment of DME
2. Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention
3. ACR Supports American Cancer Society Inclusion of CT Colonography (Virtual Colonoscopy) as Recommended Screening Tool for Colorectal Cancer in New Screening Guidelines
4. New Clinical Data Further Supports Chromium Picolinates Role in Enhancing Brain Activity in Older Adults
5. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
6. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
7. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
8. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
9. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
10. New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease
11. Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... Akcea Therapeutics, a wholly-owned subsidiary of ... today that the U.S. Food and Drug Administration ... Rx ) for the treatment of patients with ... genetic disease characterized by extremely high triglyceride levels ... study published in the NEJM in December 2014, ...
(Date:7/6/2015)... China Information Technology, Inc. (the "Company" or "CNIT") (Nasdaq ... exchange, and big data solutions in China ... mobile app for Healthcare One Pass, ushering in a ... The Company jointly hosted the launch ceremony with the ... News Net.   The mobile app for Healthcare ...
(Date:7/5/2015)... -- Nihon University is pleased to announce that ... "Medicine Definitely Jumps Up with 8K" will be ... Tokyo, Japan . Many experts on imaging ... their achievements and future prospects on progress of ... 8K technology. (Documentation: http://prw.kyodonews.jp/prwfile/release/M000079/201507031722/_prw_OA1fl_Xy4Q5W4x.pdf ) ...
Breaking Medicine Technology:Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6CNIT Launches the Mobile App for Healthcare One Pass 2CNIT Launches the Mobile App for Healthcare One Pass 3CNIT Launches the Mobile App for Healthcare One Pass 4Nihon University to Host International Symposium on Medical-Engineering Collaboration 2Nihon University to Host International Symposium on Medical-Engineering Collaboration 3
... Nov. 3 Sirion Therapeutics, Inc., a,privately ... of two investigational drugs in development for,treatment ... presented at,upcoming ophthalmology meetings: At the American ... Marriott Marquis, Atlanta),preliminary results will be presented ...
... in this Under-Studied Condition, SAN DIEGO, Nov. ... release tablets (paliperidone ER),for six weeks showed a ... study presented today at the U.S. Psychiatric & ... safety findings were similar,to published studies of paliperidone ...
Cached Medicine Technology:Durezol(TM) in the Treatment of Uveitis and Ganciclovir in the Treatment of Herpetic Keratitis: Studies of Treatments for Leading Causes of Blindness to Be Presented 2Durezol(TM) in the Treatment of Uveitis and Ganciclovir in the Treatment of Herpetic Keratitis: Studies of Treatments for Leading Causes of Blindness to Be Presented 3Durezol(TM) in the Treatment of Uveitis and Ganciclovir in the Treatment of Herpetic Keratitis: Studies of Treatments for Leading Causes of Blindness to Be Presented 4Durezol(TM) in the Treatment of Uveitis and Ganciclovir in the Treatment of Herpetic Keratitis: Studies of Treatments for Leading Causes of Blindness to Be Presented 5Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 2Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 3Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 4Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 5Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder 6
(Date:7/6/2015)... ... 2015 , ... Dr. Lawrence Green is now offering the newly FDA-approved Kybella ... a non-surgical method to dissolve fat cells and is the first of its kind ... the chin, commonly known as a double chin. Dr. Green participated in clinical trials ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... Diabetes affects ... help. More than 29 million Americans have diabetes, the majority of which are Type ... U.S. adults or more than one in three, have prediabetes (abnormally high blood sugar ...
(Date:7/5/2015)... ... July 06, 2015 , ... Security ... excited to announce the next generation of PrimeStar Individual Dental Insurance. Beginning now, ... include two network options—Maximum Allowable Charge (MAC) and usual, customary and reasonable (UCR). ...
(Date:7/5/2015)... ... July 05, 2015 , ... World Patent Marketing, ... a landscaping invention that effectively removes weeds without harming man and nature. ... Cooper, CEO and Creative Director of World Patent Marketing. "It is projected to ...
(Date:7/4/2015)... ... 2015 , ... Dating a real millionaire online can be more difficult. ... and strives to remove the worries from meeting partners. Recently, the site announced ... of 2015 and readers have responded with excitement. , “There's quite a few ...
Breaking Medicine News(10 mins):Health News:Rockville, MD Practice Now Offering New FDA-Approved Non-Surgical Double Chin Treatment 2Health News:115 Million in the U.S. could beat diabetes with the help of a new app 2Health News:Security Life Insurance Company of America Launches the Next Generation of PrimeStar Individual Dental Insurance Plans 2Health News:8 Landscaping Tips That Can Save You Money Thanks To World Patent Marketing's Innovative Landscaping Invention 2Health News:8 Landscaping Tips That Can Save You Money Thanks To World Patent Marketing's Innovative Landscaping Invention 3Health News:8 Landscaping Tips That Can Save You Money Thanks To World Patent Marketing's Innovative Landscaping Invention 4Health News:8 Landscaping Tips That Can Save You Money Thanks To World Patent Marketing's Innovative Landscaping Invention 5Health News:MillionaireMatchapp.com Publishes the Best Millionaire Dating App and Official Dating Site Reviews 2015 2
... and Diabetes Impact,the Profession, BETHESDA, Md., Feb. 7 ... lagging economy, entering the field of,podiatric medicine -- which ... in the right direction. A recent workforce study indicates,that ... to triple,their graduates between now and 2014 in order ...
... by the body can make the difference between your average ... the United States last year, reveals a new study in ... of Cell Press. , If this natural anti-cancer agent, ... might serve as a targeted chemotherapy for metastatic melanoma, a ...
... HQ, Offers Expanded Hours for Rapid HIV Testing,and ... Healing Our Land, Inc. and,Mass. Black Legislative Caucus ... Feb. 7 To commemorate the nation,s,eighth recognition ... of Massachusetts, Inc. (AAC) is collaborating to present ...
... animal fat and protein, risk did not increase, study claims ... in carbohydrates but high in animal fat and protein doesn,t ... women, a new study claims. , "One study is never ... in that it shows that a low-fat diet is no ...
... 7 AIDS Healthcare,Foundation (AHF) is proud to present ... art exhibition and auction to benefit its free,HIV/AIDS treatment, ... Vallarta, Cancun and Chiapas. Showcasing the work of notable ... of Latino art and culture will take place on ...
... Legendary Rock and Roll Hall of Famer, Marky Ramone of the ... ... NEW YORK, Feb. 7 The American Social Health Association,(ASHA) ... safer sex practices have never been more critical. Despite,hundreds of millions ...
Cached Medicine News:Health News:Looking for a Career? A New Study Shows Demand for Doctors of Podiatric Medicine to Surge Over the Next Six Years 2Health News:Natural secretion marks difference between mole and melanoma 2Health News:Natural secretion marks difference between mole and melanoma 3Health News:AIDS Action Committee Offers and Supports Variety of Events to Honor National Black HIV/AIDS Awareness Day 2Health News:Low-Carb Diets Better Than Low-Fat Diets at Preventing Diabetes 2Health News:Low-Carb Diets Better Than Low-Fat Diets at Preventing Diabetes 3Health News:Amigos y Amantes, Valentine's Day-Themed Art Auction to Benefit AIDS Healthcare Foundation's Mexico Clinics 2Health News:Amigos y Amantes, Valentine's Day-Themed Art Auction to Benefit AIDS Healthcare Foundation's Mexico Clinics 3Health News:Beating to the Drum of Safe Sex 2Health News:Beating to the Drum of Safe Sex 3
This free-standing work station safely ventilates fumes upwards, away from the work surface. Optional Exhaust Purification System features bonded charcoal filters that remove organic chemical vapors ...
... This modular benchtop fume ... fumes, allowing safe indoor release ... remove most organic contaminants. Configurations ... horizontal flow; options include final ...
... The spot fume hood mounts on a ... x 12.7mm (10" x 1/2" ) mounting ... cone is placed above the source of ... I.D. tubing which connects to an aspirator ...
... polypropylene exhaust hoods are designed to rest ... draw a stream of air across the ... operator. Other sizes and types of hoods ... are available on special order in materials ...
Medicine Products: